-
Comparison of Alignment Between EMA Indications and National Reimbursement Decisions in Italy for Orphan Drugs
Sep 9, 2025, 16:22 PM -
Incidence of Treatment-Related Adverse Events From Immune Checkpoint Inhibitors: A Meta-Analysis of Randomized Clinical Trials
Sep 9, 2025, 16:22 PM -
Evaluation of the Effectiveness of Targeted Radiofrequency Therapy in Impingement Syndrome
Sep 9, 2025, 16:22 PM -
Preliminary Real-World Results of a Community Pharmacy-Based Intervention in COPD: Evidence From the Chronic Diseases From A to Z Program
Sep 9, 2025, 16:22 PM -
Gaps in JCA Guidance for Systematic Literature Reviews: A Comparative Review with Cochrane, EUnetHTA, and Major HTA Agencies' Standards
Sep 9, 2025, 16:22 PM -
Workforce and Environmental Impact of Home-Based vs. Hospital-Based Administration of Second-Line MS Therapies in the Netherlands: A Comparative Analysis of Personnel Time and Carbon Footprint
Sep 9, 2025, 16:22 PM -
Methods for the Economic Evaluation of Health Impacts of Climate Action: When, Why, and How Best to Use Them? A Literature Review
Sep 9, 2025, 16:22 PM -
Costs Associated With the Administration, Postinfusion Monitoring, and Management of Adverse Events (AEs) Related to Novel Drugs for Second-Line (2L+) Treatment of Small-Cell Lung Cancer (SCLC)
Sep 9, 2025, 16:22 PM -
Estimating the Long-Term Impact of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Treatments on the Annual Decline of Percent-Predicted Forced Expiratory Volume in One Second (ppFEV1) Compared to Established Clinical Management...
Sep 9, 2025, 16:22 PM -
Advancing a Greener Ecosystem in Health Technology Assessment: A Review of Environmental Integration as an Additional Value Driver
Sep 9, 2025, 16:22 PM -
The Value of Rare Pediatric Disease Designation Program for Decision Making by Drug Developers
Sep 9, 2025, 16:22 PM -
Development of an LLM-Based Computable Phenotype for Pediatric Lymphoma Subtypes Using Structured and Unstructured Electronic Medical Record Data
Sep 9, 2025, 16:22 PM -
What About a Latent Cure Model? Assessing Cure Models’ Performance in Pediatric Acute Lymphoblastic Leukemia Treated With Tisagenlecleucel
Sep 9, 2025, 16:22 PM -
Adoption and Evidence Generation in NICE Early Value Assessments (EVA) for Medtech: Trends Across 2023-2025
Sep 9, 2025, 16:22 PM -
Exploring LLMs in the Conceptual and Functional Construction of Health Economic Models: A Case Study on Alzheimer's Diagnostic Cost-Effectiveness Model
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of a Digital Health Intervention for Screening and Managing Hypertension at Primary Care Level in Kenya: A Microsimulation Model
Sep 9, 2025, 16:22 PM -
Real-World Evidence Study on the Resource Impact of Subcutaneous vs. Intravenous Atezolizumab in an NHS Cancer Center
Sep 9, 2025, 16:22 PM -
Public Health and Economic Impact of RSVpreF Maternal Vaccination Among Infants in Five Asian Countries
Sep 9, 2025, 16:22 PM -
A Comprehensive Assessment of Clinical Studies on Artificial Intelligence-Enabled Interventions: Uncovering Trends and Potential Implications
Sep 9, 2025, 16:22 PM -
Surrogate Outcome Validation Within the New EU HTA Guidance Framework: Practical Considerations From an Industry Perspective Based on Experience From HTA Germany
Sep 9, 2025, 16:22 PM
